WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 21, 2005--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) and the U.S. Food and Drug Administration (FDA) have agreed to a Special Protocol Assessment (SPA) for the continued clinical development of Ramoplanin for the potential treatment of Clostridium difficile-associated disease (CDAD). By reaching consensus on the SPA, the Company has received guidance on the specific components of the Phase III program that, if completed successfully, would support regulatory approval for the indication.
